Treatment outcome and pattern of recurrence of sinonasal squamous cell carcinoma with EGFR-mutation and human papillomavirus

• Published in: Journal of cranio-maxillo-facial surgery Vol. 49; no. 6; pp. 494 - 500
• Main Authors: Nishikawa, Daisuke, Sasaki, Eiichi, Suzuki, Hidenori, Beppu, Shintaro, Sawabe, Michi, Terada, Hoshino, Sone, Michihiko, Hanai, Nobuhiro
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.06.2021
• Subjects: Alphapapillomavirus; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - genetics; EGFR mutation; ErbB Receptors - genetics; Human papillomavirus; Humans; Inverted papilloma; Mutation; Neoplasm Recurrence, Local - genetics; Papillomaviridae - genetics; Papillomavirus Infections; Paranasal Sinus Neoplasms - genetics; Paranasal Sinus Neoplasms - therapy; Retrospective Studies; Sinonasal; Squamous cell carcinoma; Treatment Outcome; EGFR mutation; Inverted papilloma; Human papillomavirus; Squamous cell carcinoma; Sinonasal
• ISSN: 1010-5182; 1878-4119
• DOI: 10.1016/j.jcms.2021.02.016

The objective of our study was to clarify the clinical features of EGFR-mutated sinonasal squamous cell carcinoma (SNSCC) and human papilloma virus (HPV)-related SNSCC. Patients with SNSCC treated from April 2008 to June 2019 at our institution were retrospectively reviewed. We examined EGFR mutation and HPV status for all patients. Main outcomes were overall survival, recurrence, and outcome of each treatment modality. A total of 85 patients with SNSCC were enrolled in this study. EGFR mutations and HPV DNA were detected in 24 (28%) and 7 (8%) patients, respectively. Patients with EGFR-mutated SNSCC showed a worse overall survival (OS) than those with EGFR wild-type in the multivariate analysis (p = 0.037). No death was observed in HPV-positive SNSCC. The cumulative incidence of local recurrence was significantly higher in EGFR mutant than EGFR wild-type tumors (p = 0.03). In patients with EGFR mutations, treatment with induction chemotherapy significantly improved OS (p = 0.01). EGFR-mutated SNSCC have a high-risk feature for recurrence and requires intensive attention for treatment and observation. A new treatment approach, such as EGFR tyrosine kinase inhibitors, may be needed.